|
Sign In to gain access to subscriptions and/or personal tools.
|
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE |
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
S. Choi and
J.N. Myers*
Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 44, Houston, TX 77030-4009, USA
Correspondence: * corresponding author, jmyers{at}mdanderson.org
The development of oral squamous cell carcinoma (OSCC) is a multistep process requiring the accumulation of multiple genetic alterations, influenced by a patients genetic predisposition as well as by environmental influences, including tobacco, alcohol, chronic inflammation, and viral infection. Tumorigenic genetic alterations consist of two major types: tumor suppressor genes, which promote tumor development when inactivated; and oncogenes, which promote tumor development when activated. Tumor suppressor genes can be inactivated through genetic events such as mutation, loss of heterozygosity, or deletion, or by epigenetic modifications such as DNA methylation or chromatin remodeling. Oncogenes can be activated through overexpression due to gene amplification, increased transcription, or changes in structure due to mutations that lead to increased transforming activity. This review focuses on the molecular mechanisms of oral carcinogenesis and the use of biologic therapy to specifically target molecules altered in OSCC. The rapid progress that has been made in our understanding of the molecular alterations contributing to the development of OSCC is leading to improvements in the early diagnosis of tumors and the refinement of biologic treatments individualized to the specific characteristics of a patients tumor.
Key Words: oral squamous cell carcinoma multistep carcinogenesis oncogene tumor suppressor gene molecular targeted therapy
Journal of Dental Research, Vol. 87, No. 1,
14-32 (2008)
DOI: 10.1177/154405910808700104

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Chiba, G. Maeda, S. Kawashiri, K. Kato, and K. Imai
Epigenetic Loss of Mucosa-Associated Lymphoid Tissue 1 Expression in Patients with Oral Carcinomas
Cancer Res.,
September 15, 2009;
69(18):
7216 - 7223.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-L. Chung, M.-Y. Lee, and N. N.M. Pui
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis
Carcinogenesis,
August 1, 2009;
30(8):
1387 - 1397.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yuvaraj, A. C. Griffin, K. Sundaram, K. L. Kirkwood, J. S. Norris, and S. V. Reddy
A Novel Function of CXCL13 to Stimulate RANK Ligand Expression in Oral Squamous Cell Carcinoma Cells
Mol. Cancer Res.,
August 1, 2009;
7(8):
1399 - 1407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.P. Barros and S. Offenbacher
Epigenetics: Connecting Environment and Genotype to Phenotype and Disease
Journal of Dental Research,
May 1, 2009;
88(5):
400 - 408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Jiang, H.S. Yang, Z. Wang, Y. Zhou, M. Zhou, X. Zeng, and Q.M. Chen
ORAOV1-A Correlates with Poor Differentiation in Oral Cancer
Journal of Dental Research,
May 1, 2009;
88(5):
433 - 438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gelbard, M. E. Kupferman, S. A. Jasser, W. Chen, A. K. El-Naggar, J. N. Myers, and E. Y. Hanna
An Orthotopic Murine Model of Sinonasal Malignancy
Clin. Cancer Res.,
November 15, 2008;
14(22):
7348 - 7357.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|